Skip to main content

Animations

MJFF Publications

7541 - 7550 of 8826 Results
Title
Year
  • Year
  • 2025
  • 2025
  • 2020
  • 2025
  • 2025
  • 2026
  • 2026
  • 2026
  • 2026
  • 2026
  • Summary Details
    OPEN
    Title: Mitochondrial complex I deficiency induces Alzheimer's disease–like signatures that are reversible by targeted therapy
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.70519
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Identifying individuals at-risk of developing Parkinson’s disease using a population-based recruitment strategy: The Healthy Brain Ageing Kassel Study
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41531-025-01008-w
    Citation Count: 2
  • Summary Details
    OPEN
    Title: The effect of LRRK2 loss-of-function variants in humans
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41591-020-0893-5
    Citation Count: 109
  • Summary Details
    OPEN
    Title: Templating of monomeric alpha-synuclein results in inflammation and SNpc dopamine neuron death in a genetic mouse model of induced synucleinopathy
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41598-025-10705-8
    Citation Count: 4
  • Summary Details
    OPEN
    Title: [18F]SynVest-1 PET imaging in people with Parkinson’s disease
    Journal Name: Brain Communications
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/braincomms/fcaf258
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.70197
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.70183
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/ana.78116
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.70205
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Three years later: tracking bothersome symptoms and impacts for people with early Parkinson’s disease
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00415-026-13615-5
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.